Development a glycosylated extracellular vesicle-derived miRNA Signature for early detection of esophageal squamous cell carcinoma

作者：Jianlin Chen, Yue Zheng, Zhen Wang, Qi Gao, Kun Hao, Xiongfeng Chen, Nantian Ke, Xiang Lv, Jiamiao Weng, Yuhong Zhong, Zhixin Huang, Mingye Fu, Lilan Zhao, Lin Fan, Hui Mi, Haijun Tang, Chundong Yu, Yi Huang · 发表于：BMC Medicine · 年份：2025 · DOI：10.1186/s12916-025-03871-z · 被引用次数：10 · 研究领域：Extracellular vesicles in disease、Nanoplatforms for cancer theranostics、Immune cells in cancer

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is often diagnosed at an advanced stage due to the lack of non-invasive early detection tools, which significantly impacts patient prognosis. Given that glycosylation alterations especially high sialylation and fucosylation, frequently occur during cellular malignant transformation, but their roles are not elucidated. We examined alterations in disease-specific glycosylated extracellular vesicles (EVs)-derived miRNAs in the serum of ESCC patients, evaluating their utility as diagnostic biomarkers. METHODS: ) was established through logistic regression in a training cohort and subsequently validated in an internal and an external multicentre cohort. RESULTS: effectively identified ESCC across all stages, demonstrating high AUC values in training (0.980), internal validation (0.957), and external multicentre validation (0.973) cohorts, markedly higher than carcinoembryonic antigen (CEA) (AUC = 0.769, training cohort; AUC = 0.749, internal validation cohort; AUC = 0.765, external validation cohort). Notably, this score exhibited robust accuracy in detecting CEA (-) ESCC cases (CEA < 5 ng/ml) (AUC = 0.974, training & internal cohort; AUC = 0.973, external multicentre validation cohort). Additionally, it displayed strong efficacy in differentiating early-stage ESCC patients (AUC = 0.982, training cohort; AUC = 0.977, external multicentre validation cohort). CONCLUSIONS: Our study illustrates the effectiveness of glycosylated EV...